Marshall S. Stanton Sells 26,132 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall S. Stanton sold 26,132 shares of the company’s stock in a transaction on Friday, June 13th. The shares were sold at an average price of $28.44, for a total value of $743,194.08. Following the transaction, the senior vice president now directly owns 79,200 shares in the company, valued at $2,252,448. The trade was a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Artivion Stock Performance

AORT opened at $28.68 on Tuesday. The company has a market cap of $1.22 billion, a PE ratio of -1,433.95 and a beta of 1.62. The stock has a 50-day moving average of $26.71 and a 200-day moving average of $27.45. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $32.33. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last released its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The company had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Trading of Artivion

Large investors have recently made changes to their positions in the stock. Legacy Advisors LLC bought a new stake in Artivion during the 1st quarter valued at approximately $28,000. MCF Advisors LLC boosted its stake in Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC boosted its stake in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after purchasing an additional 786 shares during the period. Arcadia Investment Management Corp MI bought a new stake in Artivion during the 4th quarter valued at approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion during the 4th quarter valued at approximately $64,000. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AORT shares. Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Stifel Nicolaus lowered their target price on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Finally, Citizens Jmp upgraded Artivion to a “strong-buy” rating in a research note on Tuesday, May 6th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.